[35] used the microfluidic‐based ClearCell FX system to assess for CTC in a smaller cohort of patients with advanced NSCLC and reported a CTCs detection rate of 51% with 65% PD‐L1‐positive cells. This evidence concerns the gene CD274 and non-small cell lung carcinoma.